The hpv testing and pap test market size has grown rapidly in recent years. It will grow from $4.83 billion in 2025 to $5.41 billion in 2026 at a compound annual growth rate (CAGR) of 12%. The growth in the historic period can be attributed to expansion of cervical cancer screening programs, rising awareness of women’s health issues, increased adoption of pap testing, growth of diagnostic laboratory networks, availability of standardized screening protocols.
The hpv testing and pap test market size is expected to see rapid growth in the next few years. It will grow to $8.6 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing adoption of molecular diagnostic technologies, rising demand for early cancer detection, expansion of population-based screening initiatives, growing use of automated laboratory systems, increasing healthcare investments in preventive diagnostics. Major trends in the forecast period include increasing adoption of hpv dna-based screening tests, rising use of liquid-based cytology methods, growing integration of automated diagnostic platforms, expansion of co-testing approaches for cervical screening, enhanced focus on early cancer detection accuracy.
The increasing prevalence of cervical cancer is driving growth in the HPV testing and Pap test markets. Cervical cancer is caused by uncontrolled cell growth in the cervix and is strongly linked to persistent human papillomavirus (HPV) infection. Rising incidence is largely attributed to inadequate routine screening, which limits early detection and timely treatment of precancerous lesions. HPV testing and Pap tests enable early identification of high-risk infections and cellular abnormalities, improving prevention and outcomes. For instance, in May 2025, according to Cancer Council Australia, a national nonprofit organization, 231 females in Victoria were diagnosed with invasive cervical cancer in 2023, representing a diagnosis rate of 6.4 cases per 100,000 females. Additionally, a China-based nationwide observational study conducted between January 2017 and June 2023 reported an overall HPV prevalence of 17.70% and a high-risk HPV prevalence of 13.12% among 2,728,321 women, with a secondary peak in the 61-80 age group. Therefore, rising cervical cancer prevalence is driving demand for HPV testing and Pap tests.
Major companies in the HPV and Pap test market are focusing on developing innovative solutions such as rapid, low-cost, and point-of-care screening kits to improve early detection and accessibility of cervical cancer testing. Rapid, low-cost, point-of-care screening kits are medical tests that deliver quick results, are affordable, and can be used directly at clinics or community settings without needing complex laboratory infrastructure. For instance, in April 2025, the Department of Biotechnology, an India-based government agency, launched HPV test kits for cervical cancer screening. These kits offer rapid, point-of-care detection of high-risk HPV genotypes responsible for over 96% of cervical cancer cases, enabling faster and more accurate screening. They are affordable and designed for use in resource-limited settings, facilitating widespread accessibility in rural and urban healthcare facilities. These kits aid India’s cervical cancer prevention efforts by providing a cost-effective alternative to traditional screening methods, supporting the WHO goal of 70% screening coverage by 2030.
In February 2025, Metropolis Healthcare, an India-based diagnostics company, collaborated with Roche Diagnostics to introduce HPV DNA testing in India, with the objective of enhancing early cervical cancer screening by leveraging Metropolis’ extensive national laboratory network alongside Roche’s advanced molecular diagnostics capabilities. Roche Diagnostics, a Switzerland-based healthcare and diagnostics company, is recognized for its expertise in in-vitro diagnostics, molecular testing, and oncology-focused screening solutions.
Major companies operating in the hpv testing and pap test market are Abbott Laboratories, QIAGEN N V, Becton Dickinson and Company, Hologic Inc, F Hoffmann La Roche AG, Seegene Inc, DiaSorin S p A, Genomica S A U, TruScreen Group Limited, Danaher Corporation, Siemens Healthineers AG, bioMérieux SA, Takara Bio Inc, Fujirebio Diagnostics Inc, Randox Laboratories Ltd, Quidel Corporation, Vela Diagnostics, Greiner Bio One International GmbH, Cepheid, Roche Diagnostics International AG, Genedrive plc.
North America was the largest region in the HPV testing and Pap test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global HPV testing and Pap tests market report during the forecast period. The regions covered in the hpv testing and pap test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hpv testing and pap test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the hpv testing and pap test market by increasing costs of imported diagnostic instruments, PCR systems, reagents, consumables, and laboratory automation equipment. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported testing technologies, while Asia-Pacific faces cost pressure on reagent manufacturing and exports. These tariffs are increasing test pricing and procurement costs for screening programs. At the same time, they are encouraging domestic production of diagnostic kits, localized reagent manufacturing, and regional expansion of laboratory infrastructure to support long-term testing accessibility.
The hpv testing and pap test market research report is one of a series of new reports that provides hpv testing and pap test market statistics, including hpv testing and pap test industry global market size, regional shares, competitors with a hpv testing and pap test market share, detailed hpv testing and pap test market segments, market trends and opportunities, and any further data you may need to thrive in the hpv testing and pap test industry. This hpv testing and pap test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
HPV testing and Pap tests are screening procedures utilized to identify cervical cancer in women, aiming to detect early signs of abnormal changes that could potentially lead to cancer.
The primary types of HPV testing and Pap tests include, unsurprisingly, HPV testing and Pap tests. HPV testing involves healthcare providers checking for the presence of the human papillomavirus (HPV) in a patient's body. The main products associated with these tests include instruments, consumables, and services utilizing technologies such as polymerase chain reaction (PCR), immunodiagnostics, and other relevant technologies. These screening methods find application in cervical cancer screening and vaginal cancer screening and are commonly employed by hospitals, clinics, laboratories, and various other end users.
The HPV testing and Pap test market consist of revenues earned by entities by conventional Pap test, liquid-based Pap test, HPV DNA test and co-testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The HPV testing and Pap test market also consist of sales of HPV testing and Pap test kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
The hpv testing and pap test market size is expected to see rapid growth in the next few years. It will grow to $8.6 billion in 2030 at a compound annual growth rate (CAGR) of 12.3%. The growth in the forecast period can be attributed to increasing adoption of molecular diagnostic technologies, rising demand for early cancer detection, expansion of population-based screening initiatives, growing use of automated laboratory systems, increasing healthcare investments in preventive diagnostics. Major trends in the forecast period include increasing adoption of hpv dna-based screening tests, rising use of liquid-based cytology methods, growing integration of automated diagnostic platforms, expansion of co-testing approaches for cervical screening, enhanced focus on early cancer detection accuracy.
The increasing prevalence of cervical cancer is driving growth in the HPV testing and Pap test markets. Cervical cancer is caused by uncontrolled cell growth in the cervix and is strongly linked to persistent human papillomavirus (HPV) infection. Rising incidence is largely attributed to inadequate routine screening, which limits early detection and timely treatment of precancerous lesions. HPV testing and Pap tests enable early identification of high-risk infections and cellular abnormalities, improving prevention and outcomes. For instance, in May 2025, according to Cancer Council Australia, a national nonprofit organization, 231 females in Victoria were diagnosed with invasive cervical cancer in 2023, representing a diagnosis rate of 6.4 cases per 100,000 females. Additionally, a China-based nationwide observational study conducted between January 2017 and June 2023 reported an overall HPV prevalence of 17.70% and a high-risk HPV prevalence of 13.12% among 2,728,321 women, with a secondary peak in the 61-80 age group. Therefore, rising cervical cancer prevalence is driving demand for HPV testing and Pap tests.
Major companies in the HPV and Pap test market are focusing on developing innovative solutions such as rapid, low-cost, and point-of-care screening kits to improve early detection and accessibility of cervical cancer testing. Rapid, low-cost, point-of-care screening kits are medical tests that deliver quick results, are affordable, and can be used directly at clinics or community settings without needing complex laboratory infrastructure. For instance, in April 2025, the Department of Biotechnology, an India-based government agency, launched HPV test kits for cervical cancer screening. These kits offer rapid, point-of-care detection of high-risk HPV genotypes responsible for over 96% of cervical cancer cases, enabling faster and more accurate screening. They are affordable and designed for use in resource-limited settings, facilitating widespread accessibility in rural and urban healthcare facilities. These kits aid India’s cervical cancer prevention efforts by providing a cost-effective alternative to traditional screening methods, supporting the WHO goal of 70% screening coverage by 2030.
In February 2025, Metropolis Healthcare, an India-based diagnostics company, collaborated with Roche Diagnostics to introduce HPV DNA testing in India, with the objective of enhancing early cervical cancer screening by leveraging Metropolis’ extensive national laboratory network alongside Roche’s advanced molecular diagnostics capabilities. Roche Diagnostics, a Switzerland-based healthcare and diagnostics company, is recognized for its expertise in in-vitro diagnostics, molecular testing, and oncology-focused screening solutions.
Major companies operating in the hpv testing and pap test market are Abbott Laboratories, QIAGEN N V, Becton Dickinson and Company, Hologic Inc, F Hoffmann La Roche AG, Seegene Inc, DiaSorin S p A, Genomica S A U, TruScreen Group Limited, Danaher Corporation, Siemens Healthineers AG, bioMérieux SA, Takara Bio Inc, Fujirebio Diagnostics Inc, Randox Laboratories Ltd, Quidel Corporation, Vela Diagnostics, Greiner Bio One International GmbH, Cepheid, Roche Diagnostics International AG, Genedrive plc.
North America was the largest region in the HPV testing and Pap test market in 2025. Asia-Pacific is expected to be the fastest-growing region in the global HPV testing and Pap tests market report during the forecast period. The regions covered in the hpv testing and pap test market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the hpv testing and pap test market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.
Tariffs are influencing the hpv testing and pap test market by increasing costs of imported diagnostic instruments, PCR systems, reagents, consumables, and laboratory automation equipment. Hospitals and diagnostic laboratories in North America and Europe are most affected due to reliance on imported testing technologies, while Asia-Pacific faces cost pressure on reagent manufacturing and exports. These tariffs are increasing test pricing and procurement costs for screening programs. At the same time, they are encouraging domestic production of diagnostic kits, localized reagent manufacturing, and regional expansion of laboratory infrastructure to support long-term testing accessibility.
The hpv testing and pap test market research report is one of a series of new reports that provides hpv testing and pap test market statistics, including hpv testing and pap test industry global market size, regional shares, competitors with a hpv testing and pap test market share, detailed hpv testing and pap test market segments, market trends and opportunities, and any further data you may need to thrive in the hpv testing and pap test industry. This hpv testing and pap test market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
HPV testing and Pap tests are screening procedures utilized to identify cervical cancer in women, aiming to detect early signs of abnormal changes that could potentially lead to cancer.
The primary types of HPV testing and Pap tests include, unsurprisingly, HPV testing and Pap tests. HPV testing involves healthcare providers checking for the presence of the human papillomavirus (HPV) in a patient's body. The main products associated with these tests include instruments, consumables, and services utilizing technologies such as polymerase chain reaction (PCR), immunodiagnostics, and other relevant technologies. These screening methods find application in cervical cancer screening and vaginal cancer screening and are commonly employed by hospitals, clinics, laboratories, and various other end users.
The HPV testing and Pap test market consist of revenues earned by entities by conventional Pap test, liquid-based Pap test, HPV DNA test and co-testing. The market value includes the value of related goods sold by the service provider or included within the service offering. The HPV testing and Pap test market also consist of sales of HPV testing and Pap test kits. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
This product will be delivered within 1-3 business days.
Table of Contents
1. Executive Summary
2. HPV Testing and Pap Test Market Characteristics
3. HPV Testing and Pap Test Market Supply Chain Analysis
4. Global HPV Testing and Pap Test Market Trends and Strategies
5. HPV Testing and Pap Test Market Analysis of End Use Industries
7. Global HPV Testing and Pap Test Strategic Analysis Framework, Current Market Size, Market Comparisons and Growth Rate Analysis
8. Global HPV Testing and Pap Test Total Addressable Market (TAM) Analysis for the Market
9. HPV Testing and Pap Test Market Segmentation
10. HPV Testing and Pap Test Market Regional and Country Analysis
11. Asia-Pacific HPV Testing and Pap Test Market
12. China HPV Testing and Pap Test Market
13. India HPV Testing and Pap Test Market
14. Japan HPV Testing and Pap Test Market
15. Australia HPV Testing and Pap Test Market
16. Indonesia HPV Testing and Pap Test Market
17. South Korea HPV Testing and Pap Test Market
18. Taiwan HPV Testing and Pap Test Market
19. South East Asia HPV Testing and Pap Test Market
20. Western Europe HPV Testing and Pap Test Market
21. UK HPV Testing and Pap Test Market
22. Germany HPV Testing and Pap Test Market
23. France HPV Testing and Pap Test Market
24. Italy HPV Testing and Pap Test Market
25. Spain HPV Testing and Pap Test Market
26. Eastern Europe HPV Testing and Pap Test Market
27. Russia HPV Testing and Pap Test Market
28. North America HPV Testing and Pap Test Market
29. USA HPV Testing and Pap Test Market
30. Canada HPV Testing and Pap Test Market
31. South America HPV Testing and Pap Test Market
32. Brazil HPV Testing and Pap Test Market
33. Middle East HPV Testing and Pap Test Market
34. Africa HPV Testing and Pap Test Market
36. HPV Testing and Pap Test Market Competitive Landscape and Company Profiles
37. HPV Testing and Pap Test Market Other Major and Innovative Companies
40. HPV Testing and Pap Test Market High Potential Countries, Segments and Strategies
41. Appendix
List of Tables
Executive Summary
HPV Testing And Pap Test Market Global Report 2026 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses hpv testing and pap test market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase:
- Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
- Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on end user analysis.
- Benchmark performance against key competitors based on market share, innovation, and brand strength.
- Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
- Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
- Report will be updated with the latest data and delivered to you along with an Excel data sheet for easy data extraction and analysis.
- All data from the report will also be delivered in an excel dashboard format.
Description
Where is the largest and fastest growing market for hpv testing and pap test? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The hpv testing and pap test market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
- The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
- The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
- The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
- The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
- The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
- The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
- The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
- The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
- Market segmentations break down the market into sub markets.
- The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
- Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
- The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
- The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.
Report Scope
Markets Covered:
1) By Test Type: HPV Testing; Pap Test2) By Product: Instruments; Consumables; Services
3) By End User: Hospitals And Clinics; Laboratories; Other End Users
Subsegments:
1) By HPV Testing: High-Risk HPV Testing; HPV Genotyping2) By Pap Test: Conventional Pap Test; Liquid-Based Pap Test; Pap Plus HPV Testing
Companies Mentioned: Abbott Laboratories; QIAGEN N V; Becton Dickinson and Company; Hologic Inc; F Hoffmann La Roche AG; Seegene Inc; DiaSorin S p A; Genomica S A U; TruScreen Group Limited; Danaher Corporation; Siemens Healthineers AG; bioMérieux SA; Takara Bio Inc; Fujirebio Diagnostics Inc; Randox Laboratories Ltd; Quidel Corporation; Vela Diagnostics; Greiner Bio One International GmbH; Cepheid; Roche Diagnostics International AG; Genedrive plc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain
Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time Series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita.
Data Segmentation: Country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: Word, PDF or Interactive Report + Excel Dashboard
Added Benefits:
- Bi-Annual Data Update
- Customisation
- Expert Consultant Support
Companies Mentioned
The companies featured in this HPV Testing and Pap Test market report include:- Abbott Laboratories
- QIAGEN N V
- Becton Dickinson and Company
- Hologic Inc
- F Hoffmann La Roche AG
- Seegene Inc
- DiaSorin S p A
- Genomica S A U
- TruScreen Group Limited
- Danaher Corporation
- Siemens Healthineers AG
- bioMérieux SA
- Takara Bio Inc
- Fujirebio Diagnostics Inc
- Randox Laboratories Ltd
- Quidel Corporation
- Vela Diagnostics
- Greiner Bio One International GmbH
- Cepheid
- Roche Diagnostics International AG
- Genedrive plc
Table Information
| Report Attribute | Details |
|---|---|
| No. of Pages | 250 |
| Published | February 2026 |
| Forecast Period | 2026 - 2030 |
| Estimated Market Value ( USD | $ 5.41 Billion |
| Forecasted Market Value ( USD | $ 8.6 Billion |
| Compound Annual Growth Rate | 12.3% |
| Regions Covered | Global |
| No. of Companies Mentioned | 22 |
